Results 91 to 100 of about 983 (198)
Sleep, 2023 Excessive daytime sleepiness (EDS) is a symptom of Obstructive Sleep Apnea (OSA) that can persist despite primary airway therapy and can be managed with wake-promoting agents.
Y. Winter +10 more
semanticscholar +1 more source
Dose Determinations at Drug Approval Reviews: FDA‐Approved Drugs in Past 5 Years
Clinical Pharmacology &Therapeutics, Volume 117, Issue 6, Page 1743-1753, June 2025.Drug dose appropriateness is one of the most discussed issues in regulatory reviews. We analyzed dose determinations during Food and Drug Administration (FDA) drug reviews to determine whether there were changes between the proposed and approved doses of new molecular entities (NMEs), including cases where postmarketing dose‐finding studies were ...
Sachiko Mita, Shunsuke Ono
wiley +1 more source
Journal of Sleep Research, Volume 34, Issue 3, June 2025.Cognitive Behavioural Therapy for Nightmares, alone or in combination with targeted lucidity reactivation, significantly reduced nightmare frequency and severity, leading to remission of nightmare disorder in four of six participants. Sleep talking, NREM parasomnia symptoms, and self‐efficacy for managing symptoms also improved significantly.
Jennifer M. Mundt +12 more
wiley +1 more source
The electroretinography to identify biomarkers of idiopathic hypersomnia and narcolepsy type 1
Journal of Sleep Research, Volume 34, Issue 1, February 2025.Summary Hypersomnia spectrum disorders are underdiagnosed and poorly treated due to their heterogeneity and absence of biomarkers. The electroretinography has been proposed as a proxy of central dysfunction and has proved to be valuable to differentiate certain psychiatric disorders.
Héloïse Rach +10 more
wiley +1 more source
Pharmacology Research &Perspectives, Volume 12, Issue 1, February 2024.Flow diagram of data collection and analysis of pitolisant‐associated adverse events. Abstract Pitolisant, a novel histamine H3‐receptor antagonist, holds significant promise for treating narcolepsy. However, a petition, which highlighted that pitolisant was associated with deaths during clinical trials, has propelled it into the spotlight of ...
Cheng Jiang +5 more
wiley +1 more source
Drug Testing and Analysis, Volume 16, Issue 1, Page 5-29, January 2024.Abstract In this 16th edition of the annual banned‐substance review on analytical approaches in human sports drug testing, literature on recent developments in this particular section of global anti‐doping efforts that was published between October 2022 and September 2023 is summarized and discussed.
Mario Thevis, Tiia Kuuranne, Hans Geyer
wiley +1 more source
Barriers to therapy adherence in narcolepsy [PDF]
BackgroundTreatment adherence (TA) in narcolepsy is a complex phenomenon influenced by various factors beyond patient-related aspects. The management of narcolepsy involves non-pharmacological and symptomatic pharmacological treatment.
Bourke, A.M. +7 more
core +2 more sources
The effect and safety of sleep interventions on suicidal thoughts and behavior – A systematic review and meta-analyses [PDF]
Background: Sleep disturbances are a risk factor for suicidal ideation, suicide attempts and suicide. While recent findings suggest that improving sleep by psychotherapeutic sleep interventions exerts a positive effect on suicidality, there are also ...
Antypa, Niki +9 more
core +1 more source
Solriamfetol Titration & AdministRaTion (START): Characteristics of Patients with Obstructive Sleep Apnoea and Prescriber Rationale for Starting Treatment with Solriamfetol [PDF]
Pneumologie, 2021 H. Singh +6 more
openaire +1 more source
Narcolepsia à luz dos conhecimentos atuais e perspetivas futuras na gestão desta patologia [PDF]
A narcolepsia é um distúrbio neurológico, que se caracteriza por uma hipersonolência diurna, associada a um conjunto de outros sintomas. Esta patologia pode cursar com episódios de perda de força muscular súbita sem perda de consciência (cataplexia ...
Calvo, Ana Patricia Pereira
core